Research statistics

ARA 290 (Cibinetide) research: publications and trials

What has been published on ARA 290 (Cibinetide): PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether ARA 290 (Cibinetide) works or is safe. For what it is and what the studies found, see the ARA 290 (Cibinetide) profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

75

Since 2011

Publications in 2026 so far

5

Through November 15, 2026

Human clinical research

10.7%

8 of 75 classified

Registered clinical trials

4

ClinicalTrials.gov

Randomized controlled trials

4

Publications reporting an RCT in people

Systematic reviews and meta-analyses

1

Preclinical studies

68.0%

43 animal · 8 in vitro · 0 computational

Records that only mention it

8

Not counted above

Status in the library: In clinical trials. Groups: Tissue-repair peptides.

Publications by year

ARA 290 (Cibinetide) publications by year and evidence

2011, Preclinical (animal, in vitro, computational): 3 of 32012, Human clinical research: 1 of 32012, Preclinical (animal, in vitro, computational): 2 of 32013, Human clinical research: 2 of 112013, Preclinical (animal, in vitro, computational): 6 of 112013, Reviews and meta-analyses: 2 of 112013, Other and not yet classified: 1 of 112014, Preclinical (animal, in vitro, computational): 5 of 82014, Reviews and meta-analyses: 2 of 82014, Other and not yet classified: 1 of 82015, Human clinical research: 2 of 62015, Preclinical (animal, in vitro, computational): 2 of 62015, Reviews and meta-analyses: 2 of 62016, Preclinical (animal, in vitro, computational): 5 of 72016, Reviews and meta-analyses: 2 of 72017, Human clinical research: 1 of 52017, Preclinical (animal, in vitro, computational): 4 of 52018, Human clinical research: 1 of 42018, Preclinical (animal, in vitro, computational): 3 of 42019, Preclinical (animal, in vitro, computational): 1 of 12020, Human clinical research: 1 of 42020, Preclinical (animal, in vitro, computational): 3 of 42021, Preclinical (animal, in vitro, computational): 5 of 62021, Other and not yet classified: 1 of 62022, Preclinical (animal, in vitro, computational): 3 of 32023, Preclinical (animal, in vitro, computational): 1 of 12024, Preclinical (animal, in vitro, computational): 3 of 42024, Reviews and meta-analyses: 1 of 42025, Preclinical (animal, in vitro, computational): 4 of 42026 (to date), Preclinical (animal, in vitro, computational): 1 of 52026 (to date), Reviews and meta-analyses: 4 of 5Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05101520112015201920232026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
201103003
201212003
2013262111
201405218
201522206
201605207
201714005
201813004
201901001
202013004
202105016
202203003
202301001
202403104
202504004
2026 (to date)01405

Study types

Animal study43
Review12
In vitro study8
Randomized controlled trial4
Editorial, letter or other3
Other clinical trial2
Observational human study2
Systematic review1

Research areas

From MeSH major topics. A paper can be in several areas.

Neurological and mental health31
Immune system28
Tissue repair24
Cardiovascular16
Metabolic health12
Endocrinology11
Cognitive health4
Dermatology3
Musculoskeletal3
Reproductive and sexual health3
Gastrointestinal2
Antimicrobial and infectious disease1

Registered clinical trials

0 of 2 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 2 · Terminated: 1 · Unknown status: 1
Phase 1 / Phase 2: 1 · Phase 2: 3

TrialStatusPhaseStartedResults
The Use of ARA290 for the Treatment of Diabetic Macular OedemaNCT06626971 · 9 enrolledTerminatedPhase 22016-04—
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisNCT02039687 · 64 enrolledCompletedPhase 22014-01Posted
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)NCT01933529 · 24 enrolledUnknown statusPhase 22013-10—
Cognitive and Neural Effects of ARA290NCT02070783 · 36 enrolledCompletedPhase 1, Phase 22012-02—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Managing fatigue in sarcoidosis - A systematic review of the evidence.

    Chronic respiratory disease · August 9, 2016 · Systematic review · cited 40 times · open access

    PMID 27507833 · DOI 10.1177/1479972316661926 · Reviews and meta-analyses

  2. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

    Investigative ophthalmology & visual science · May 1, 2017 · Randomized controlled trial · cited 104 times · open access

    PMID 28475703 · DOI 10.1167/iovs.16-21291 · Human clinical research

  3. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · September 18, 2015 · Randomized controlled trial · cited 11 times

    PMID 26431906 · DOI 10.1016/j.euroneuro.2015.09.005 · Human clinical research

  4. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

    Molecular medicine (Cambridge, Mass.) · November 8, 2013 · Randomized controlled trial · cited 95 times · open access

    PMID 24136731 · DOI 10.2119/molmed.2013.00122 · Human clinical research

  5. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

    Molecular medicine (Cambridge, Mass.) · November 15, 2012 · Randomized controlled trial · cited 112 times · open access

    PMID 23168581 · DOI 10.2119/molmed.2012.00332 · Human clinical research

  6. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

    Journal of clinical medicine · July 14, 2020 · Other clinical trial · cited 11 times · open access

    PMID 32674280 · DOI 10.3390/jcm9072225 · Human clinical research

  7. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

    Molecular medicine (Cambridge, Mass.) · March 13, 2015 · Other clinical trial · cited 144 times · open access

    PMID 25387363 · DOI 10.2119/molmed.2014.00215 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

    Molecular medicine (Cambridge, Mass.) · March 13, 2015 · Other clinical trial · cited 144 times · open access

    PMID 25387363 · DOI 10.2119/molmed.2014.00215 · Human clinical research

  2. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

    Molecular medicine (Cambridge, Mass.) · November 15, 2012 · Randomized controlled trial · cited 112 times · open access

    PMID 23168581 · DOI 10.2119/molmed.2012.00332 · Human clinical research

  3. Co-delivery of a growth factor and a tissue-protective molecule using elastin biopolymers accelerates wound healing in diabetic mice.

    Biomaterials · June 30, 2017 · Animal study · cited 106 times

    PMID 28688286 · DOI 10.1016/j.biomaterials.2017.06.043 · Animal studies

  4. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

    Investigative ophthalmology & visual science · May 1, 2017 · Randomized controlled trial · cited 104 times · open access

    PMID 28475703 · DOI 10.1167/iovs.16-21291 · Human clinical research

  5. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

    Molecular medicine (Cambridge, Mass.) · November 8, 2013 · Randomized controlled trial · cited 95 times · open access

    PMID 24136731 · DOI 10.2119/molmed.2013.00122 · Human clinical research

Latest publications

  1. Regenerative peptides for inferior alveolar nerve injury: a narrative review.

    Frontiers in dental medicine · October 27, 2026 · Review · cited 0 times · open access

    PMID 43011877 · DOI 10.3389/fdmed.2026.1977522 · Reviews and meta-analyses

  2. Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases.

    Frontiers in oral health · September 30, 2026 · Review · cited 0 times · open access

    PMID 42876687 · DOI 10.3389/froh.2026.1907109 · Reviews and meta-analyses

  3. Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.

    Current pain and headache reports · August 24, 2026 · Review · cited 0 times

    PMID 42635865 · DOI 10.1007/s11916-026-01542-z · Reviews and meta-analyses

  4. Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

    Neurobiology of disease · April 1, 2026 · Animal study · cited 0 times · open access

    PMID 41933665 · DOI 10.1016/j.nbd.2026.107376 · Animal studies

  5. Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.

    Frontiers in neurology · January 23, 2026 · Review · cited 0 times · open access

    PMID 41659975 · DOI 10.3389/fneur.2025.1665405 · Reviews and meta-analyses

  6. ARA290 Attenuates Apical Periodontitis via SIRT1/NF-κB/IL-1β Pathway Modulation.

    International dental journal · July 17, 2025 · Animal study · cited 5 times · open access

    PMID 40680515 · DOI 10.1016/j.identj.2025.100863 · Animal studies

  7. ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury.

    European journal of pharmacology · April 9, 2025 · Animal study · cited 5 times

    PMID 40216181 · DOI 10.1016/j.ejphar.2025.177610 · Animal studies

  8. Mechanisms of ARA290 in counteracting cadmium-triggered neurotoxicity in PC12 cells.

    Toxicology research · February 17, 2025 · In vitro study · cited 12 times · open access

    PMID 39968520 · DOI 10.1093/toxres/tfaf023 · In vitro studies

  9. Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.

    Investigative ophthalmology & visual science · January 1, 2025 · Animal study · cited 2 times · open access

    PMID 39775697 · DOI 10.1167/iovs.66.1.13 · Animal studies

  10. The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.

    International immunopharmacology · June 28, 2024 · Review · cited 5 times

    PMID 38943972 · DOI 10.1016/j.intimp.2024.112452 · Reviews and meta-analyses

Browse all 75 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: ARA 290; Cibinetida; Cibinetide; PHβSP

((TITLE_ABS:"ARA 290" OR CHEM:"ARA 290" OR TITLE_ABS:"ARA290" OR CHEM:"ARA290") OR (TITLE_ABS:"Cibinetida" OR CHEM:"Cibinetida") OR (TITLE_ABS:"Cibinetide" OR CHEM:"Cibinetide") OR (TITLE_ABS:"PHβSP" OR CHEM:"PHβSP" OR TITLE_ABS:"PHbetaSP" OR CHEM:"PHbetaSP")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). ARA 290 (Cibinetide) research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/ara-290